Review Papers Against Their Own Results

Concise critique of Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells

Bottom line: The authors present a robust bump-and-hole engineering pipeline that identifies orthogonal IMiD ligand ZF degron pairs (best: WEIS degron with bumped IMiD compound 23) that selectively degrade engineered POIs while largely sparing endogenous CRL4CRBN neosubstrates across multiple human cell lines; methods combine focused medicinal chemistry, an 8380-sequence ZF library screen, proteomics, docking and cellular validation — overall an important, reproducible advance for molecular glue/degron tool development for target validation with clear limitations for in vivo/mouse use and need for structural confirmation.

Key evidences: selective WEIS/23 degradation (35-fold selectivity vs WT in flow assay; NanoLuc/DC50 and TRIM28 HiBiT degradation shown; TMT proteomics showing minimal off-targets for 23) and comprehensive library-based residue mapping that links positions 147/149/150/154 to selectivity and mechanism.

Representative sources: primary ACS Chemical Biology paper reporting the WEIS/23 system and methods ACS Chemical Biology orthogonal degron study

Representative complementary preprint (original 2024 bioRxiv reporting similar pipeline) bioRxiv preprint orthogonal degron

Suggested next steps: solve an experimentally determined ternary structure (cryoEM/x-ray) of CRL4CRBN:23:WEIS ternary complex; test endogenous gene knock-in of WEIS in several POIs in multiple cell types; engineer mouse-compatible CRBN/degron variants for in vivo work.

Detailed review and critique: Orthogonal IMiD-Degron Pairs Induce Selective Protein Degradation in Cells

Visual summary

1) What the paper does, concisely

The authors develop a bump-and-hole chemical biology pipeline that: (a) synthesizes bumped IMiD analogues, (b) constructs and screens an 8380-member mutant zinc finger (ZF) degron library in Jurkat cells using a ratiometric EGFP:mCherry flow assay and NGS, (c) identifies orthogonal ligand-degron pairs (best: compound 23 paired with WEIS degron), (d) validates degradation of multiple POIs fused to WEIS in different human cell lines, and (e) uses quantitative TMT proteomics to demonstrate minimal off-target degradation by compound 23 compared to WT IMiDs (pomalidomide) that degrade many endogenous ZF neosubstrates.
Key published/full dataset and methods are in the ACS Chemical Biology paper (peer-reviewed) ACS Chemical Biology orthogonal degron study

2) Strengths and why the advance matters

• Large combinatorial screen: An 8380-sequence ZF library (positions 147,149,150,154 varied systematically) gives broad and interpretable sequence space for selectivity mapping, increasing confidence that WEIS/23 is not a chance hit Library design and NGS screen
• High biochemical and cellular selectivity: Compound 23 degrades WEIS-tagged fusions with up to 35-fold selectivity vs WT DG; proteomics (TMT) across multiple cell types shows negligible endogenous degradation by 23 while pomalidomide depletes many neosubstrates TMT proteomics selectivity
• Small degron size: WEIS is ~60 aa (~7 kDa) — much smaller than dTAG, HaloTag, Bromotag — better tolerated for CRISPR knock-in and less likely to perturb POI function WEIS degron size and small molecule
• Toolable for undruggable proteins: They demonstrate degradation of TRIM28, CDK9, HPRT1, NanoLuc: shows potential for target validation of proteins lacking ligands TRIM28 degradation proof-of-concept

3) Limitations, blindspots, and critical caveats

• Mouse compatibility not solved: mouse CRBN carries V388I that blocks IMiD recruitment; WEIS/23 shows modest activity in 3T3 cells — in vivo mouse work requires CRBN engineering or degron re-optimization Mouse cereblon limitation
• Structural models are docking-based: FoldX/Rosetta/GOLD docking rationalize contacts (e.g., E149–Y355, W147 cation-pi with 23), but authors acknowledge lack of experimental ternary complex structure (cryo-EM/x-ray) — docking can mislead ternary PPI dynamics Docking-based mechanistic proposals
• Engineered tag still exogenous: most applications used exogenous overexpressed WEIS-POI fusions (lentiviral); only TRIM28 used CRISPR knockout/replace strategy — general effects of tagging on endogenous protein function and expression need wider demonstration Reliance on exogenous fusion constructs
• Proteome breadth limited to selected cell lines: TMT proteomics across Jurkat, ESCs, MM.1S are solid, but other cell types and primary cells remain to be tested; potential tissue-specific off-targets unknown Proteomics scope and limits

4) Technical reproducibility and transparency

Methods are described thoroughly in the ACS article and supporting information (plasmids, NGS sequences, chemistry, proteomics data in supporting figures). The library screen used 3 biological replicates and low-MOI lentiviral transduction to favor single integrants — good screening practice. Data and supporting info link provided by the authors (Supporting Information at ACS) Supporting Information link

5) Mechanistic interpretation and open questions

• Authors propose that selectivity arises from combined effects: mutation-introduced new polar contacts (E149–Y355), hydrophobic substitutions at 150, and specific interactions between ligand bump (e.g., N-methylpiperazine of 23) forming salt bridges to CRBN and cation-pi with W147 — plausible but requires ternary structural confirmation via cryo-EM/x-ray (cf. recent cryo-EM insights into IMiD ternaries) CryoEM reveals cryptic pockets in IMiD ternaries
• Time-course DC50 behavior of WEIS/23 indicates rapid action but variable DC50 across time (lower at 6 h than at 24 h) — consistent with compound metabolism/export and reversibility; HPLC shows compound 23 stability decline by 24 h; practical implication: dosing schedule matters for knockdown experiments and potential therapeutic applications Kinetics and compound stability

6) Recommendations for users and next experiments

1. Obtain an experimental ternary structure (cryo-EM or X-ray) of CRL4CRBN:23:WEIS to confirm predicted salt bridges/cation-pi interactions and to guide improved ligand design (reduce off-target risk and improve mouse compatibility) Value of cryo-EM for ternary complexes
2. Engineer mouse-compatible CRBN or adapt degron sequences to mouse CRBN pocket variants so in vivo genetics and pharmacology can be performed (or use humanized CRBN mice) Mouse CRBN incompatibility note
3. Test endogenous CRISPR knock-in of WEIS at several POIs across cell types and measure functional consequences (activity, localization) before invoking degradation experiments; monitor resource competition for degradation capacity (see Nature Comm resource competition work) Degron resource competition concerns

7) Short, actionable takeaways for experimentalists

• WEIS/23 is an excellent cell biology tool for conditional, selective degradation of tagged POIs in human cells with minimal CRBN neosubstrate collateral damage — use it for target validation if you can tag POI cleanly (CRISPR preferred) Practical experimental utility of WEIS/23
• Expect species-specific compatibility issues; do not assume mouse works without testing or CRBN engineering Species compatibility caveat

8) Relevance to broader targeted protein degradation field

This approach complements PROTACs, other degron systems (dTAG, HaloPROTAC, S4D) and newer programmable strategies (ClickRNA-PROTAC, enzyme-activatable PROTACs), offering a small-degron + small-molecule glue combination that minimizes neosubstrate effects via chemical orthogonality — valuable as a modular target validation tool prior to drug discovery pipelines ClickRNA-PROTAC context

9) Final assessment

The work is high-quality, methodologically sound, and provides an immediately usable degron/molecular glue tool (WEIS/23) for cell-based target validation with excellent selectivity against endogenous neosubstrates in tested human cell lines. The principal limitations are species translation (mouse CRBN incompatibility), docking-based mechanistic claims lacking an experimental ternary structure, and the need for deeper validation with endogenous knock-in of WEIS across diverse primary cell types. With those caveats, this paper is an important advance (see scored metrics below).

Citations used in this review

• ACS Chemical Biology orthogonal degron study
• bioRxiv orthogonal degron preprint
• eLife MDC selective degradation
• Cryo-EM of CRL4CRBN-IKZF3 complexes
• Resource competition for degradation

Interactive next steps

If you want me to run an iterative bioinformatics/structural analysis (docking, ternary modeling, degron compatibility checks, off-target prediction on human proteome, design mouse-adapted degron variants), click:

Author review buttons

If you want deeper outputs (ternary-structure modeling, proteome-wide off-target prediction, or design of mouse-adapted degrons), press Run AI Biology Analysis above.